17-AZ

Home 17-AZ

Back to list

go to website

17 AstraZeneca UK Limited (AZ)

Investigator Name: Darren Hodgson

Organization: Oncology R&D

Function: Executive Director Clinical Biomarker Development

Role in GUIDE.MRD (brief description): AstraZeneca is contributing funding and expertise in ctDNA assay development and clinical implementation.

Expectation of GUIDE.MRD (brief description): AstraZeneca is delighted to participate in GUIDE.MRD and expects the project to reduce the time taken for the evaluation of MRD tests and the subsequent clinical adoption of those that benefit patients.

E-mail address: darren.hodgson@astrazeneca.com

All the Partners

01 Universitaetsklinikum Hamburg-Eppendorf (UKE) – Germany
02 Aarhus Universitet (AU) – Denmark
03 Academisch Ziekenhuis Groningen (UMCG) – Netherlands
04 Centre Hospitalier Universitaire de Nice (CHUNICE) – France
05 Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncológicas Carlos III (FPS-CNIO) – Spain
06 LungenClinic Grosshansdorf GMBH (LUNGEN-CG) – Germany
07 Karolinska Institutet (KI) – Sweden
08 Illumina Cambridge Limited (ILLUMINA) – United Kingdom
09 Horizon Discovery Limited (HDL) – United Kingdom
10 LGC Clinical Diagnostics INC (LGC) – United States
11 The Synergist (SYNERGIST) – Belgium
12 Digestive Cancers Europe DICE (DiCE) – Belgium
13 Amgen (Europe) GMBH (AMGEN) – Switzerland
14 Bristol-Myers Squibb Company Corp (BMS) – United States
15 F. Hoffmann-La Roche AG (ROCHE) – Switzerland
16 Innovation Acta (INN-ACTA) – Italy
17 AstraZeneca UK Limited (AZ) – United Kingdom
18 Medizinische Universitat Graz (MUG) – Austria
19 Synergist Services (SYNERSERV) – Belgium
20 Asociatia Centrul Pentru Inovatie in Medicina (INOMED) – Romania
21 Centre Hospitalier Universitaire Montpellier (CHUM) – France
22 Aarhus Universitetshospital (AUH) – Denmark
23 Region Stockholm (KH) – Sweden
24 Lung Cancer Europe LUCE (LuCE) – Switzerland
25 AbbVie (AbbVie)

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066.
The JU receives support from the European Union’s Horizon Europe research and innovation programme and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics INC.
Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.